Samsung’s Q2 operating profit halves amid sluggish chip sales
Samsung Electronics Co.'s operating profit in the second quarter missed market expectations, with a 56% on-year fall, as its mainstay semiconductor ...
S.Korea’s pension fund NPS posts weaker returns amid US tariff concerns
The National Pension Service (NPS), South Korea’s state-run pension fund and the country’s largest institutional investor, is posting sh...
Even barcodes copied: Counterfeits invasion threatens K-brands
Counterfeit Korean beauty, fashion and food products are surging on overseas e-commerce platforms, with lookalike packaging making them hard to dist...
Loss-making Lotte Chemical to sell water treatment unit to Synopex
Lotte Chemical Corp., South Korea’s second-largest petrochemical company grappling with mounting losses amid a prolonged industry downturn, wi...
Lotte Biologics signs antibody drug CMO deal with UK’s Ottimo Pharma
BOSTON – Lotte Biologics Co. has signed a deal to manufacture an antibody therapy for British biotech startup Ottimo Pharma as the South Korea...
Asian manufacturing activity stumbles again under weight of Trump tariffs
Factory activity slowed across much of Asia in May as uncertainty over U.S. tariffs continued to cause steep declines in new orders, purchasing ma...
NPS logs 0.87% return from first-quarter investment
The National Pension Service (NPS), South Korea’s state-run pension fund and the country’s largest institutional investor, announced on ...
Samsung Biologics to spin off biosimilar unit Samsung Bioepis
Samsung Biologics Co., the world’s largest contract drugmaker, will undergo a strategic split to separate its contract development and manufac...
South Korea’s Rznomics inks $1.3 bn out-licensing deal with Eli Lilly
Rznomics Inc., a South Korean RNA therapeutics developer, has signed an agreement worth more than $1.3 billion with US pharmaceutical giant Eli Lill...
SK Group seeks to sell SK Signet as part of sweeping portfolio realignment
South Korea’s second-largest conglomerate SK Group is seeking to divest SK Signet Inc., four years after acquiring the EV charger manufacturin...
Mubadala, Goldman Sachs to invest $700 mn in Kakao Mobility
United Arab Emirates’ sovereign wealth fund Mubadala Investment Co. and Goldman Sachs are set to invest a combined $700 million in Kakao Mobil...
Celltrion unveils cancer medicine to expand new drug pipelines
South Korea’s leading biosimilar drug developer Celltrion Inc. on Sunday unveiled an anticancer medicine to expand new pipelines and accelerat...
Celltrion expands footprint in Latin America with flagship oncology drugs
South Korea’s biopharmaceutical giant Celltrion Inc. has solidified its presence in South America after winning supply contracts for its flags...
Celltrion wins Australian approval for eye, bone disease biosimilars
Celltrion Inc. said Wednesday it has received regulatory approval from Australia’s Therapeutic Goods Administration (TGA) for three biosimilar...
Kakao Entertainment sheds loss-making units, revives IPO prospects
Kakao Entertainment Corp. has been divesting unprofitable music labels and digital content platforms, which it has gobbled up over the past few year...
Celltrion to sell autoimmune drug Stelara biosimilar at Costco in US
South Korea’s leading biosimilar drug developer Celltrion Inc. said on Monday it is set to sell Steqeyma, a biosimilar to autoimmune disease t...
SillaJen: First to use lab-grown human tissue to find best cancer drug dose
South Korean biotechnology firm SillaJen Inc. is pioneering a new approach to determine the best dose for a cancer drug combination in clinical tria...
Samsung in 'do or die' situation'; Lee sounds crisis alarm
Samsung Electronics Co. Chairman Lee Jae-yong has warned the company's executives that the South Korean tech giant has lost its characteristic "rele...
China stock funds outperform US funds in South Korea
Chinese stocks are attracting South Korean investors looking beyond Wall Street amid the downturn in US Big Tech stocks.South Korea’s equity f...
South Korea’s pension fund NPS risks massive loss from Homeplus fiasco
South Korea’s National Pension Service (NPS), the nation’s biggest institutional investor, could lose more than 1 trillion won ($692 mil...
South Korea’s forex reserves dip to nearly 5-year low in February
South Korea’s foreign exchange reserves diminished to the lowest level in nearly five years last month, largely due to the expanded forex swap...
Chong Kun Dang to build new plant for foray into biologics market
Chong Kun Dang Pharmaceutical Corp. is discussing building a research center and a plant in Siheung, about 30 kilometers southwest of Seoul, with th...
Celltrion wins EU approval for autoimmune disease treatment Avtozma
Celltrion Inc.’s Avtozma, a biosimilar to Roche’s autoimmune disease treatment Actemra, has won approval from the European Commission, f...
One-third of Korean petrochem bonds incur valuation losses
South Korean institutional investors, including banks, insurers and securities companies, have yet to fully benefit from recent declines in bond yie...
SK Hynix surpasses Samsung with record-high profit in Q4
SK Hynix Inc., the top supplier of high-bandwidth memory (HBM) chips to Nvidia Corp., on Thursday reported its highest-ever quarterly profit of 8.08...
Lotte Biologics eyes first ADC CDMO order in 2025
SAN FRANCISCO -- Lotte Biologics Co., the drug consignment development and production unit of South Korean conglomerate Lotte Group, will seek to wi...
Celltrion seeks large-scale M&A in Q4, eyes 2027 Nasdaq debut
SAN FRANCISCO – South Korea’s leading biosimilar drug developer Celltrion Inc. seeks to acquire a domestic health food maker as early as...
SK Biopharmaceuticals, Eurofarma to set up AI epilepsy platform JV in US
South Korea’s SK Biopharmaceuticals Co. has signed a deal with Brazil’s Eurofarma Laboratórios S.A. to establish a joint venture ...
LG Energy logs 1st quarterly loss in over 3 years, outlook remains gloomy
LG Energy Solution Ltd. reported its first quarterly loss in more than three years on Thursday, adding to concerns that the world’s third-larg...
Yuhan’s lung cancer drug gets OK in Europe
Leclaza (ingredient: lazertinib), a new lung cancer treatment developed by South Korea’s Yuhan Corp. secured approval from the European Commis...
